Shannon Lantzy MedCrypt New VP of Consulting

Lantzy Will Leverage Her Regulatory Science & Business Transformation Experience fron Working with Booz Allen Hamilton, the FDA, & NASA to Launch MedCrypt's Consulting Services

MedCrypt the proactive cybersecurity solution provider for medical devices, today announced the addition of Shannon Lantzy, Ph.D., as their new Vice President of Consulting.

Prior to joining MedCrypt, Shannon Lantzy spent six years with Booz Allen Hamilton where she led the Regulatory Science Innovation team, partnering with the U.S. Food and Drug Administration (FDA) to develop, test, and evaluate new approaches to regulatory decisions and benefit-risk assessments.

Shannon Lantzy also co-founded Booz Allen’s Secure Connected Health practice and brought together a diverse set of experts, cybersecurity tools, and strategies to solve cybersecurity challenges relating to patient safety. Before Booz Allen, Lantzy was a consultant for NASA, helping with organizational strategy, capability assessment, enterprise architecture, technology adoption, and process improvement. Lantzy earned a Ph.D. in Information Systems from Robert H. Smith School of Business at the University of Maryland.

“Advancements in connected technology have paved the way for a future of healthcare that is digital and delivered in new environments,” said Shannon Lantzy, MedCrypt Vice President of Consulting. “To build this digital landscape and to support future innovation, healthcare needs a baseline of secure infrastructure. The MedCrypt team is working with some of the world’s largest medical device manufacturers to improve their medical device security posture and I am both eager and proud to join in on their efforts.”

At MedCrypt, Shannon Lantzy will be responsible for leading MedCrypt’s Consulting Services to bring clinically innovative medical devices that are secure by design through their lifecycle. She will lead and support consulting engagements, ensuring MedCrypt’s customers meet their business outcomes and the pre-and post-market cybersecurity guidelines from the FDA.

“I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future,” said Mike Kijewski, CEO of MedCrypt. “We’re excited to have Shannon join our team to help our customers transform from reactive to proactive product security.”

SourceMedCrypt

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”